

BREAKING NEWS

S LAUNCHES VERSION 2.0 OF PERSONAL GENOMICS TEST, DNAwise



Dalmia Healthcare starts clinical trial with its Ayurvedic composition to treat COVID-19





MEDICAL BIOTECHNOLOGY

ANTIBIOTICS

PHARMACEUTICAL BIOTECH

VACCINES

ANNOUNCEMENTS





Home / Medical Biotechnology / INDUS HEALTH PLUS LAUNCHES VERSION 2.0 OF PERSONAL GENOMICS TEST, DNAwise



MEDICAL BIOTECHNOLOGY

INDUS HEALTH PLUS **LAUNCHES VERSION 2.0** OF PERSONAL GENOMICS **TEST, DNAwise**

Indus Health Plus, a pioneer in the preventive healthcare sector, launched **DNAwise 2.0**, a revolutionary personal genomics test. It is a genetic test that decodes the genetic makeup and informs an individual about the predisposition for various health conditions. Besides, it helps to understand the best diet and fitness regime for a person.

The advanced DNAwise 2.0 has expanded its horizon of genetic analysis by incorporating 17 new

parameters under Heath, Nutrition and Fitness. In addition, a new category - 'Habit' has also been introduced which reports on three parameters: Alcohol Dependence, Caffeine Consumption, and Nicotine Dependence. It has been observed that people have a tendency for high consumption of alcohol, caffeine, and nicotine in many forms like smoking, tobacco chewing etc. GENETICS play an important role in determining the tendency for above mentioned habits (addictions) along with various psychological and environmental factors.

DNAwise 2.0 is a saliva-based user-friendly genetic test that can be done from the comfort of home. Indus Health Plus has a strong network across the country that provides door – to – door sample collection service for consumers.

Mr. Amol Naikawadi, Joint Managing Director, Indus Health Plus said, "The up-gradation in technology and our expertise in the field of genetics stimulated us to bring a unique platform of prevention. With the current COVID 19 situation, people have understood that maintaining Good Health is most important and prevention is the only best step. In an endeavor to create a healthy future for individuals by expanding the umbrella of prevention, we have launched DNAwise 2.0. It analyses the health conditions, habits, Nutrition & fitness traits based on one's genetics. It can empower people to personalize their health checkups and make informed lifestyle modifications/choices. Knowing the genetic predispositions to various health parameters helps an individual to delay/prevent the onset of the health condition by modifying lifestyle."

"With the launch of DNAwise 2.0, we are propelling our mission to make healthcare accessible, available, and affordable. At Indus Health Plus, we believe that the culture of prevention and healthy wellbeing should start at an early age" added Mr. Naikawadi.

The package is available pan India, at an affordable price and includes saliva sample kit, reports, and counseling by a genetic counselor. The test reports are more comprehensive and consumer friendly. Testing and reporting involve cutting edge technology and international standards.

DNAwise 1.0 genetic test was launched in December 2018 and received tremendous response amongst the consumers and empowered them to live a happy and healthy life. The consumers are also taking their genetic report to their doctors, fitness trainers and dieticians for more benefits and help in lifestyle personalization. DNAwise is a once-in-a-lifetime investment for health that is recommended for every family member to know the predisposition to different health conditions, followed by yearly health examination. The genetic test report can be a guide for one's lifelong wellness.

Tags: Amol Naikawadi | DNAwise 2.0 | Indus Health Plus

Previous

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar **Bevacizumab for Review**

Leave a Reply

Your email address will not be published. Required fields are marked * Comment

Name *

Email *

Website

☐ Save my name, email, and website in this browser for the next time I comment.

Post Comment


MORE STORIES



ANNOUNCEMENTS MEDICAL BIOTECHNOLOGY

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review

2 May 31, 2020 Trade News Network



ANNOUNCEMENTS MEDICAL BIOTECHNOLOGY

Mylan and Lupin Announce Positive CHMP Opinion for Nepexto®, Biosimilar Etanercept ② May 31, 2020
☑ Trade News Network



MEDICAL BIOTECHNOLOGY

Mylan Invalidates Sanofi's Lantus® SoloSTAR® **Device Patents in IPR Proceedings**

2 May 29, 2020 Trade News Network

Search ...

Search

CURRENT NEWS

INDUS HEALTH PLUS LAUNCHES VERSION 2.0 OF PERSONAL GENOMICS TEST, DNAwise

Dalmia Healthcare starts clinical trial with its Ayurvedic composition to treat COVID-19

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review

Fujifilm Invests \$83M USD to Expand FUJIFILM Diosynth Biotechnologies Microbial Capacity

Mylan and Lupin Announce Positive CHMP Opinion for Nepexto®, Biosimilar Etanercept

CATEGORIES

Announcements

Antibiotics

Medical Biotechnology **Nutrient Supplementation**

Pharmaceutical Biotech

Vaccines

YOU MAY HAVE MISSED







